• +1-646-491-9876
    • +91-20-67278686

    Search

    Radiation Injury - Pipeline Review, H1 2017

    Radiation Injury - Pipeline Review, H1 2017

    • Report Code ID: RW0001709471
    • Category Pharmaceuticals
    • No. of Pages 47
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Radiation Injury - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H1 2017, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

    Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Radiation Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 8, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Radiation Injury - Overview
    Radiation Injury - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Radiation Injury - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Radiation Injury - Companies Involved in Therapeutics Development
    FirstString Research Inc
    PharmaIN Corp
    Synedgen Inc
    Windtree Therapeutics Inc
    Radiation Injury - Drug Profiles
    Aerosurf - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMX-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-2E2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-2E5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Des-Asp Angiotensin 1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DG-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granexin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSJ-0017 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    molgramostim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SYGN-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VEDA-1209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Radiation Injury - Dormant Projects
    Radiation Injury - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Radiation Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Radiation Injury - Pipeline by FirstString Research Inc, H1 2017
    Radiation Injury - Pipeline by PharmaIN Corp, H1 2017
    Radiation Injury - Pipeline by Synedgen Inc, H1 2017
    Radiation Injury - Pipeline by Windtree Therapeutics Inc, H1 2017
    Radiation Injury - Dormant Projects, H1 2017
    Radiation Injury - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Radiation Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    FirstString Research Inc
    PharmaIN Corp
    Synedgen Inc
    Windtree Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//radiation-injury-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//radiation-injury-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//radiation-injury-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments